{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:25:06Z","timestamp":1785410706051,"version":"3.56.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.1182\/bloodadvances.2023012462","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T20:43:31Z","timestamp":1721767411000},"page":"4751-4755","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged \u226550 years with hemophilia A or B"],"prefix":"10.1182","volume":"8","author":[{"given":"Doris","family":"Quon","sequence":"first","affiliation":[{"name":"1Orthopaedic Hemophilia Treatment Center, Luskin Orthopaedic Institute for Children, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Jackson","sequence":"additional","affiliation":[{"name":"2Providence Health Care, St. Paul\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Alvarez-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"3Department of Hematology, University Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-8597","authenticated-orcid":false,"given":"Umer","family":"Khan","sequence":"additional","affiliation":[{"name":"4Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casiano","sequence":"additional","affiliation":[{"name":"4Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7367-133X","authenticated-orcid":false,"given":"Savita","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"6Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"suppl 6","key":"2024092411510457500_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"suppl 77","key":"2024092411510457500_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ejh.12497","article-title":"The ageing patient with haemophilia","volume":"94","author":"Canaro","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024092411510457500_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.13353","article-title":"Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein","volume":"24","author":"Oldenburg","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"2024092411510457500_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024092411510457500_bib5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"key":"2024092411510457500_bib6","first-page":"229","article-title":"Comorbidities, health-related quality of life, health-care utilization in older persons with Hemophilia-Hematology Utilization Group Study part VII (HUGS VII)","volume":"13","author":"Curtis","year":"2022","journal-title":"J\u00a0Blood Med"},{"issue":"1","key":"2024092411510457500_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/asheducation-2015.1.41","article-title":"Managing older patients with hemophilia","volume":"2015","author":"Angelini","year":"2015","journal-title":"Hematology"},{"key":"2024092411510457500_bib8","doi-asserted-by":"crossref","first-page":"20406207231166779","DOI":"10.1177\/20406207231166779","article-title":"Efficacy and safety of damoctocog alfa pegol prophylaxis in patients \u2a7e40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study","volume":"14","author":"Reding","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"S2","key":"2024092411510457500_bib9","first-page":"18","article-title":"People with haemophilia including female carriers in Nordic countries die at an earlier age and have significant co-morbidities","volume":"27","author":"Steen Carlsson","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"2024092411510457500_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2024092411510457500_bib11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024092411510457500_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"2024092411510457500_bib13","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/hae.14036","article-title":"Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study","volume":"26","author":"Pasi","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"2024092411510457500_bib14","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","article-title":"Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study","volume":"4","author":"Fischer","year":"2017","journal-title":"Lancet Haematol"},{"issue":"26","key":"2024092411510457500_bib15","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"K\u00f6nigs","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024092411510457500_bib16","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/bloodadvances.2020004085","article-title":"Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B","volume":"5","author":"Nolan","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2024092411510457500_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2024092411510457500_bib18","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/diagnostics12122937","article-title":"Cardiovascular risk factors in patients with congenital hemophilia: a focus on hypertension","volume":"12","author":"Badescu","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"2024092411510457500_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/HYPERTENSIONAHA.113.01174","article-title":"Prevalence and risk factors for hypertension in hemophilia","volume":"62","author":"von Drygalski","year":"2013","journal-title":"Hypertension"},{"issue":"2","key":"2024092411510457500_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/hae.12539","article-title":"Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand","volume":"21","author":"Oldenburg","year":"2015","journal-title":"Haemophilia"},{"issue":"5-6","key":"2024092411510457500_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000437299","article-title":"Depression and quality of life in older persons: a review","volume":"40","author":"Sivertsen","year":"2015","journal-title":"Dement Geriatr Cogn Disord"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4751\/2243719\/blooda_adv-2023-012462-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4751\/2243719\/blooda_adv-2023-012462-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:59:10Z","timestamp":1727182750000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4751\/517123\/Long-term-clinical-outcomes-of-prophylaxis-with-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012462","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}